Gonadotropin and sex steroid levels in HIV-infected premenopausal women and their association with subclinical atherosclerosis in HIV-infected and -uninfected women in the Women's Interagency HIV Study (WIHS)

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 4, 2013, Pages

  Karim, Roksana ^a,b,e   Mack, Wendy J ^a,b   Kono, Naoko ^b   Tien, Phyllis C ^c,d   Anastos, Kathryn ^e   Lazar, Jason ^f   Young, Mary ^g   Cohen, Mardge ^h   Golub, Elizabeth ⁱ   Greenblatt, Ruth M ^c   Kaplan, Robert C ^j   Hodis, Howard N ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

^g GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^h RUSH UNIVERSITY   (United States)

ⁱ JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN; GONADOTROPIN; INHIBIN B; PRASTERONE SULFATE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTERIAL WALL THICKNESS; ARTERY COMPLIANCE; ARTICLE; B SCAN; COMMON CAROTID ARTERY; CONTROLLED STUDY; DEHYDROEPIANDROSTERONE SULPHATE BLOOD LEVEL; DISEASE ASSOCIATION; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBIN B BLOOD LEVEL; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX STEROID BLOOD LEVEL; SUBCLINICAL ATHEROSCLEROSIS; TESTOSTERONE BLOOD LEVEL;

ADULT; ASYMPTOMATIC DISEASES; ATHEROSCLEROSIS; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; FEMALE; GONADAL STEROID HORMONES; GONADOTROPINS; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PREMENOPAUSE; WOMEN'S HEALTH;

EID: 84876275598     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3195     Document Type: Article

References (51)

1. Isles CG, Hole DJ, Hawthorne VM, Lever AF. Relation between coronary risk and coronary mortality in women of the Renfrew and paisley survey: comparison with men. Lancet. 1992;339:702-706.
2. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J. 1987; 114:413-419.
3. Kannel WB, Wilson PW. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med. 1995;155:57-61.
4. Bairey Merz CN, Johnson BD, Sharaf BL, et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored wise study. J Am Coll Cardiol. 2003;41:413-419.
5. Golden SH, Maguire A, Ding J, et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol. 2002; 155:437-445.
6. Karim R, Hodis HN, Stanczyk FZ, Lobo RA, Mack WJ. Relationship between serum levels of sex hormones and progression of subclinical atherosclerosis in postmenopausal women. J Clin Endocrinol Metab. 2008;93:131-138.
7. Phillips GB, Jing TY, Laragh JH. Serum sex hormone levels in postmenopausal women with hypertension. J Hum Hypertens. 1997; 11:523-526.
8. Phillips GB, Pinkernell BH, Jing TY. Relationship between serum sex hormones and coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol. 1997;17:695-701.
9. Reinecke H, Bogdanski J, Woltering A, et al. Relationofserum levels of sex hormone binding globulin to coronary heart disease in postmenopausal women. Am J Cardiol. 2002;90:364-368.
10. Rexrode KM, Manson JE, Lee IM, et al. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation. 2003;108:1688-1693.
11. Sutton-Tyrrell K, Wildman RP, Matthews KA, et al. Sex-hormonebinding globulin and the free and rogen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation. 2005;111:1242-1249.
12. Currier JS, Havlir DV. Complications of HIV disease and antiretroviral therapy. Top HIV Med. 2009;17:57-67.
13. Palella FJ Jr, Phair JP. Cardiovascular diseasein HIV infection. Curr Opin HIV AIDS. 2011;6:266-271.
14. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41:194-200.
15. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145:397-406.
16. Cotter AG, Powderly WG. Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. Best Pract Res Clin Endocrinol Metab. 2011;25:501-515.
17. Cofrancesco J Jr, Shah N, Ghanem KG, et al. The effects of illicit drug use and HIV infection on sex hormone levels in women. Gynecol Endocrinol. 2006;22:244-251.
18. Grinspoon S, Corcoran C, Stanley T, Rabe J, Wilkie S. Mechanisms of and rogen deficiency in human immunodeficiency virus-infected women with thewasting syndrome. J Clin Endocrinol Metab. 2001; 86:4120-4126.
19. Huang JS, Wilkie SJ, Dolan S, et al. Reduced testosterone levels in human immunodeficiency virus-infected women with weight loss and low weight. Clin Infect Dis. 2003;36:499-506.
20. Santoro N, Arnsten JH, Buono D, Howard AA, Schoenbaum EE. Impact of street drug use, HIV infection, and highly active antiretroviral therapy on reproductive hormones in middle-aged women. J Womens Health (Larchmt). 2005;14:898-905.
21. Santoro N, Lo Y, Moskaleva G, et al. Factors affecting reproductive hormones in HIV-infected, substance-using middle-aged women. Menopause. 2007;14:859-865.
22. Kandathil AJ, Kannangai R, David S, et al. Human immunodeficiency virus infection and levels of dehydroepiandrosterone sulfate in plasma among Indians. Clin Diagn Lab Immunol. 2005;12: 1117-1118.
23. Cejtin HE, Kalinowski A, Bacchetti P, et al. Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction. Obstet Gynecol. 2006;108:1423-1431.
24. Ohl J, Partisani M, Demangeat C, Binder-Foucard F, Nisand I, Lang JM. [Alterations of ovarian reserve tests in human immunodeficiency virus (HIV)-infected women]. Gynecol Obstet Fertil. 2010; 38:313-317.
25. Ferreira CE, Pinto-Neto AM, Conde DM, Costa-Paiva L, Morais SS, Magalhaes J. Menopause symptoms in women infected with HIV: prevalence and associated factors. Gynecol Endocrinol. 2007;23: 198-205.
26. Schoenbaum EE, Hartel D, Lo Y, Howard AA, Floris-Moore M, Arnsten JH, Santoro N. HIV infection, drug use, and onset of natural menopause. Clin Infect Dis. 2005;41:1517-1524.
27. Grinspoon S, Corcoran C, Miller K, et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab. 1997;82:1332-1337.
28. Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol. 2002;90:3F-6F.
29. Lee YW, Eum SY, Nath A, Toborek M. Estrogen-mediated protection against HIV TAT protein-induced inflammatory pathways in human vascular endothelial cells. Cardiovasc Res. 2004;63:139-148.
30. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev. 2003;24:313-340.
31. Li J, Al-Azzawi F. Mechanism of and rogen receptor action. Maturitas. 2009;63:142-148.
32. Perusquia M, Stallone JN. Do and rogens play a beneficial role in the regulation of vascular tone? Nongenomic vascular effects of testosterone metabolites. Am J Physiol Heart Circ Physiol. 2010;298: H1301-H1307.
33. Campelo AE, Cutini PH, Massheimer V. Testosterone modulates platelet aggregation and endothelial cell growth through nitric oxide pathway. J Endocrinol. 2012;213(1):77-87.
34. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9:117-125.
35. Kaplan RC, Kingsley LA, Gange SJ, et al. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS. 2008;22:1615-1624.
36. Seaberg EC, Benning L, Sharrett AR, et al. Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke. 2010;41:2163-2170.
37. Selzer RH, Mack WJ, Lee PL, Kwong-Fu H, Hodis HN. Improved common carotid elasticity and intima-media thickness measurements from computer analysis of sequential ultrasound frames. Atherosclerosis. 2001;154:185-193.
38. Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, Gorbach SL. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;31:803-805.
39. Huang JS, Wilkie SJ, Sullivan MP, Grinspoon S. Reduced bone density in and rogen-deficient women with acquired immune deficiency syndrome wasting. J Clin Endocrinol Metab. 2001;86:3533-3539.
40. Bernini GP, Moretti A, Sgro M, et al. Influence of endogenous and rogens on carotid wall in postmenopausal women. Menopause. 2001;8:43-50.
41. Bernini GP, Sgro M, Moretti A, et al. Endogenous and rogens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab. 1999;84:2008-2012.
42. Mantzoros CS, Georgiadis EI, Young R, et al. Relative and rogenicity, blood pressure levels, and cardiovascular risk factors in young healthy women. Am J Hypertens. 1995;8:606-614.
43. Webb CM, Collins P. Testosterone and coronary artery disease in men. Maturitas. 2010;67:15-19.
44. Bowles DK, Maddali KK, Ganjam VK, et al. Endogenous testosterone increases l-type CA2 + channel expression in porcine coronary smooth muscle. Am J Physiol Heart Circ Physiol. 2004;287:H2091-H2098.
45. Gonzales RJ, Krause DN, Duckles SP. Testosterone suppresses endothelium-dependent dilation of rat middle cerebral arteries. Am J Physiol Heart Circ Physiol. 2004;286:H552-H560.
46. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992;75:1092-1098.
47. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86:4261-4267.
48. Yaron M, Greenman Y, Rosenfeld JB, et al. Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men. Eur J Endocrinol. 2009;160:839-846.
49. Braunstein GD, Reitz RE, Buch A, Schnell D, Caulfield MP. Testosterone reference ranges in normally cycling healthy premenopausal women. J Sex Med. 2011;8:2924-2934.
50. Massafra C, De Felice C, Agnusdei DP, Gioia D, Bagnoli F. Androgens and osteocalcin during the menstrual cycle. J Clin Endocrinol Metab. 1999;84:971-974.
51. Salonia A, Pontillo M, Nappi RE, et al. Menstrual cycle-related changes in circulating and rogens in healthy women with self-reported normal sexual function. J Sex Med. 2008;5:854-863.